The Urgo Group
Healing People since 1958
The UrgoTouch® laser is owned by the Urgo Group, a french company with a 100% family-owned shareholder base enabling it to undertake bold projects and to anchor long-term investments. The Urgo Group is a global leader in wound care.
About the Urgo Group
Since its creation in 1958, the Urgo Group has been working on changing patient’s lives through innovative healthcare and healing solutions. Our international cutting-edge research laboratories allow us to guarantee our patients best-in-class products with clinically proven effectiveness.
With decades of expertise, Urgo is a global pioneer in wound care, backed by cutting-edge research, clinical innovation, and partnerships with leading healthcare institutions. Our solutions—trusted by professionals worldwide—are designed to accelerate healing, reduce complications, and improve patient comfort. Recognized with prestigious awards like the Prix Galien, Urgo combines scientific rigor, advanced technology, and a patient-first approach to set the standard in wound and skin care.
862M€
2024 Turnover
3,800
employees
300M€
R&D Investments
(2020 – 2030)
20
countries
Urgo’s artificial skin revolution
The Genesis project
Urgo is tackling a major scientific challenge with the GENESIS project: pioneering artificial skin to transform the severe wounds care, such as burns. Currently, autografting is the only solution, but it’s complex, costly, and requires long hospital stays.
A Consortium of Excellence backed by the French state :
- Établissement Français du Sang (expertise in biotechnology),
- Dassault Systèmes (virtual modeling),
- LBTI (CNRS/Université Lyon 1) (tissue biology research),
- A laboratory from AFM-Téléthon.
GENESIS has secured €22.8M in funding through public & private stakeholders.
Urgo Surgical
Urgo Surgical is a business unit within the Urgo Group. It was founded in 2017 and provides cutting edge innovations aiming to optimize acts of aesthetic surgery.
UrgoTouch® is the first product in the Urgo Surgical portfolio. Its developement spans over more than 15 years, showing the Urgo’s commitment to R&D, excellence and patient wellbeing.
Urgo Surgical is currently present in the French and Spanish markets where more than 40,000 patients have benefited from our treatment.
in 2023, Urgo Surgical extended its portfolio by launching Retix.C®, a dermo-aesthetic brandaiming to stimulate skin’s natural regeneration processes.
Our team
